As of November 6, 2026, Fennec Pharmaceuticals Inc. is a publicly traded company (Nasdaq: FENC); its largest reported holder is Rosalind Advisors, Inc., with 9.6% on Schedule 13G/A of August 13, 2026, then Kam Lawrence (8.2%) (Schedule 13G/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Fennec Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Fennec Pharmaceuticals Inc. a real, registered company?
- Fennec Pharmaceuticals Inc. files with the SEC under CIK 1211583 (its SEC filings).
- Its shares are listed under the ticker FENC on Nasdaq (SEC company record).
- Incorporated in A1; business address in Research Triangle Park, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under FENNEC PHARMACEUTICALS INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Rostislav Raykov (Form 8-K filed 2026-04-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Orin Hirschman (filed 2026-10-19).
Who are Fennec Pharmaceuticals Inc.'s owners and officers?
Fennec Pharmaceuticals Inc.: business address in Research Triangle Park, North Carolina; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-19).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-19 | Orin Hirschman | 7.1% |
| Schedule 13G/A, 2026-08-14 | Solas Capital Management, LLC | 5.4% |
| Schedule 13G/A, 2026-08-14 | Southpoint Master Fund, LP | 0% |
| Schedule 13G/A, 2026-08-13 | Rosalind Advisors, Inc. | 9.6% |
| Schedule 13G/A, 2026-05-15 | Solas Capital Management, LLC | 7.2% |
| Schedule 13G/A, 2026-05-14 | Rosalind Advisors, Inc. | 8.8% |
| Schedule 13G, 2026-04-28 | Orin Hirschman | 5.7% |
| Schedule 13G/A, 2026-02-17 | Kam Lawrence | 8.2% |
| Schedule 13G/A, 2026-02-11 | Rosalind Advisors, Inc. | 9.8% |
| Schedule 13G/A, 2026-01-14 | Southpoint Master Fund, LP | 8% |
| Schedule 13G, 2025-11-13 | Rosalind Advisors, Inc. | 7.5% |
Questions about who owns Fennec Pharmaceuticals Inc.
Who owns Fennec Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Fennec Pharmaceuticals Inc.: Rosalind Advisors, Inc. (9.6%, Schedule 13G/A, filed 2026-08-13), Kam Lawrence (8.2%, Schedule 13G/A, filed 2026-02-17), Orin Hirschman (7.1%, Schedule 13G/A, filed 2026-10-19) and Solas Capital Management, LLC (5.4%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Fennec Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Fennec Pharmaceuticals Inc. on this page are Rosalind Advisors, Inc. (9.6%), Kam Lawrence (8.2%) and Orin Hirschman (7.1%).
When did Rosalind Advisors, Inc. buy into Fennec Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rosalind Advisors, Inc. on this page is the Schedule 13G, filed 2025-11-13, reporting 7.5%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Fennec Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Fennec Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fennec Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-28 | Rostislav Raykov | departed |
Which insiders own Fennec Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Southpoint GP, LP, a 10% owner: 2,744,741 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Southpoint Capital Advisors LP, a 10% owner: 2,744,741 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Southpoint GP, LLC, a 10% owner: 2,744,741 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- , a 10% owner: 2,744,741 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
- Southpoint Capital Advisors LLC, a 10% owner: 2,744,741 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-29).
Shares outstanding: 35,067,159 as of 2026-08-11, from the company's latest SEC cover page.
How much has Fennec Pharmaceuticals Inc. raised?
No fundraising or offering filing from Fennec Pharmaceuticals Inc. is on file with us.
Keep reading
More on Fennec Pharmaceuticals Inc. and the records around it.
Fennec Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Southpoint Master Fund, LP also filed stake reports on 2 other companies: Dentsply Sirona Inc. (Aug 2026), Ibotta, Inc. (Aug 2025)
- Solas Capital Management, LLC also filed stake reports on 5 other companies: MAIA Biotechnology, Inc. (Aug 2026), Modular Medical, Inc. (Aug 2026), SANUWAVE Health, Inc. (Aug 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), REGENTIS BIOMATERIALS LTD. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/fennec-pharmaceuticals